Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: Implications for amyloid-modifying therapies

Annals of Neurology

Volumn 73, Issue 4, 2013, Pages 449-458

  Piazza, Fabrizio ^a   Greenberg, Steven M ^b   Savoiardo, Mario ^c   Gardinetti, Margherita ^a   Chiapparini, Luisa ^c   Raicher, Irina ^d   Nitrini, Ricardo ^d   Sakaguchi, Hideya ^e   Brioschi, Monica ^f   Billo, Giuseppe ^g   Colombo, Antonio ^h   Lanzani, Francesca ^h   Piscosquito, Giuseppe ^c   Carriero, Maria Rita ^c   Giaccone, Giorgio ^c   Tagliavini, Fabrizio ^c   Ferrarese, Carlo ^a   Difrancesco, Jacopo C ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e KUMAMOTO UNIVERSITY   (Japan)

^f OSPEDALE NIGUARDA CA GRANDA   (Italy)

^g SAN BORTOLO HOSPITAL   (Italy)

^h DESIO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN AUTOANTIBODY; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; AUTOANTIBODY; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; MALE; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; VASCULAR AMYLOIDOSIS;

ADULT; AGED; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; AUTOANTIBODIES; BRAIN; CASE-CONTROL STUDIES; CEREBRAL AMYLOID ANGIOPATHY; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PHOSPHORYLATION; RETROSPECTIVE STUDIES; STEROIDS; TAU PROTEINS;

EID: 84878407495     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23857     Document Type: Article

References (38)

1. Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011; 7: 367-385.
2. Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012; 11: 241-249.
3. Coric V, van Dyck CH, Salloway S, et al. Safety and tolerability of the gamma-Secretase Inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 2012; 69: 1430-1440.
4. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012; 69: 198-207.
5. Schroeter S, Khan K, Barbour R, et al. Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci 2008; 28: 6787-6793.
6. Pfeifer M, Boncristiano S, Bondolfi L, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002; 298: 1379.
7. Eng JA, Frosch MP, Choi K, et al. Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol 2004; 55: 250-256.
8. Scolding NJ, Joseph F, Kirby PA, et al. Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain 2005; 128: 500-515.
9. Kinnecom C, Lev MH, Wendell L, et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology 2007; 68: 1411-1416.
10. Savoiardo M, Erbetta A, Storchi G, Girotti F,. Case 159: cerebral amyloid angiopathy-related inflammation. Radiology 2010; 256: 323-327.
11. Savoiardo M, Erbetta A, Di Francesco JC, et al. Cerebral amyloid angiopathy-related inflammation: an emerging disease. Neuroradiol J 2011; 24: 253-257.
12. DiFrancesco JC, Brioschi M, Brighina L, et al. Anti-Abeta autoantibodies in the CSF of a patient with CAA-related inflammation: a case report. Neurology 2011; 76: 842-844.
13. Boche D, Denham N, Holmes C, Nicoll JA,. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol 2010; 120: 369-384.
14. Melzer N, Harder A, Gross CC, et al. CD4+ T cells predominate in cerebrospinal fluid and leptomeningeal and parenchymal infiltrates in cerebral amyloid beta-related angiitis. Arch Neurol 2012; 69: 773-777.
15. Chung KK, Anderson NE, Hutchinson D, et al. Cerebral amyloid angiopathy related inflammation: three case reports and a review. J Neurol Neurosurg Psychiatry 2011; 82: 20-26.
16. Knudsen KA, Rosand J, Karluk D, Greenberg SM,. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 2001; 56: 537-539.
17. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005; 58: 840-846.
18. Sakaguchi H, Ueda A, Kosaka T, et al. Cerebral amyloid angiopathy-related inflammation presenting with steroid-responsive higher brain dysfunction: case report and review of the literature. J Neuroinflammation 2011; 8: 116.
19. Renard D, Castelnovo G, Wacongne A, et al. Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria. J Neurol 2012; 259: 2429-2433.
20. Sjogren M, Vanderstichele H, Agren H, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 2001; 47: 1776-1781.
21. Bulbarelli A, Lonati E, Brambilla A, et al. Abeta42 production in brain capillary endothelial cells after oxygen and glucose deprivation. Mol Cell Neurosci 2012; 49: 415-422.
22. Piazza F, Galimberti G, Conti E, et al. Increased tissue factor pathway inhibitor and homocysteine in Alzheimer's disease. Neurobiol Aging 2012; 33: 226-233.
23. Tibolla G, Norata GD, Meda C, et al. Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. Atherosclerosis 2010; 210: 78-87.
24. Ferrarese C, Piazza F,. Vascular damage and neurodegeneration. J Alzheimers Dis 2012; 29: 23-24.
25. Du Y, Dodel R, Hampel H, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 2001; 57: 801-805.
26. Song MS, Mook-Jung I, Lee HJ, et al. Serum anti-amyloid-beta antibodies and Alzheimer's disease in elderly Korean patients. J Int Med Res 2007; 35: 301-306.
27. Weksler ME, Relkin N, Turkenich R, et al. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 2002; 37: 943-948.
28. Conti E, Galimberti G, Tremolizzo L, et al. Cholinesterase inhibitor use is associated with increased plasma levels of anti-Abeta 1-42 antibodies in Alzheimer's disease patients. Neurosci Lett 2010; 486: 193-196.
29. Baril L, Nicolas L, Croisile B, et al. Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer's disease and control subjects. Neurosci Lett 2004; 355: 226-230.
30. Hyman BT, Smith C, Buldyrev I, et al. Autoantibodies to amyloid-beta and Alzheimer's disease. Ann Neurol 2001; 49: 808-810.
31. Nath A, Hall E, Tuzova M, et al. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolecular Med 2003; 3: 29-39.
32. Conti E, Galimberti G, Piazza F, et al. Increased soluble APPalpha, Abeta 1-42, and anti-Abeta 1-42 antibodies in plasma from down syndrome patients. Alzheimer Dis Assoc Disord 2010; 24: 96-100.
33. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372: 216-223.
34. Blennow K, Zetterberg H, Rinne JO, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 2012; 69: 1002-1010.
35. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009; 73: 2061-2070.
36. Greenberg SM, Frosch MP,. Life imitates art: anti-amyloid antibodies and inflammatory cerebral amyloid angiopathy. Neurology 2011; 76: 772-773.
37. Gurol ME, Dierksen G, Betensky R, et al. Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy. Neurology 2012; 79: 320-326.
38. Yang L, Rieves D, Ganley C,. Brain amyloid imaging - FDA approval of florbetapir F18 injection. N Engl J Med 2012; 367: 885-887.